GPR84 Antibody - #DF2769

Figure 2 Prognostic significance of MRGPI-based groups. (A) Multivariate Cox regression analysis of 13 differentially expressed macrophage-related hub genes. (B) Cox regression analysis of the MRGPI and clinicopathological parameters based on the TCGA cohort. Covariates including age, gender, IDH mutation, ATRX mutation, MGMT promoter methylation status, TERT promoter mutation, and MRGPI were included in the initial univariate Cox regression. Covariates with p-values less than 0.01 were further included in the multivariate Cox model. (C, D) K-M analysis of the survival and tumor progression-free interval differences between MRGPI-based groups based on TCGA, CGGA325, and Gravendeel GBM cohorts. (E, F) Immunohistochemical staining of five genes at the protein level. The tissue was divided into core of the tumor (Tumor) and the margin containing infiltrating tumor cells (Peritumor) in three patients with a pathological diagnosis of GBM. The intensity of staining for the proteins encoded by these genes at the tissue level ranged from negative to positive, with E showing genes with significantly higher IHC scores in the tumor core. The IHC scores of the five genes were shown in F (Scale bar, 100μm). (G) Pan-cancer-based MRGPI prognostic significance. Samples were split into early (PFI < 6 months) and late (PFI > 12 months) relapse groups based on PFI. OV, Ovarian serous cystadenocarcinoma; LUAD, Lung adenocarcinoma; LUSC, Lung squamous cell carcinoma; PRAD, Prostate adenocarcinoma; BLCA, Bladder urothelial carcinoma; TGCT, Testicular germ cell tumors; ESCA, Esophageal carcinoma; PAAD, Pancreatic adenocarcinoma; LIHC, Liver hepatocellular carcinoma; KIRP, Kidney renal papillary cell carcinoma; SARC, Sarcoma; BRCA, Breast invasive carcinoma; MESO, Mesothelioma; COAD, Colon adenocarcinoma; STAD, Stomach adenocarcinoma; SKCM, Skin cutaneous melanoma; CHOL, Cholangiocarcinoma; KIRC, Kidney renal clear cell carcinoma; THCA, Thyroid carcinoma; UCEC, Uterine corpus endometrial carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; HNSC, Head and neck squamous cell carcinoma; READ, Rectum adenocarcinoma; LGG, Lower grade glioma; KICH, Kidney chromophobe; UCS, Uterine carcinosarcoma; ACC, Adrenocortical carcinoma; PCPG, Pheochromocytoma and paraganglioma; UVM, Uveal melanoma. ***p < 0.001. ns, non significant.